Denosumab Administration After Spinal Cord Injury
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01983475|
Recruitment Status : Unknown
Verified March 2019 by William A. Bauman, M.D., James J. Peters Veterans Affairs Medical Center.
Recruitment status was: Recruiting
First Posted : November 14, 2013
Last Update Posted : March 8, 2019
|Condition or disease||Intervention/treatment||Phase|
|Osteoporosis Spinal Cord Injury||Drug: Denosumab Drug: Placebo (identical Denosumab volume of normal saline)||Phase 4|
The primary objective of this study is to test the efficacy of a potent anti-resorptive agent, denosumab [receptor activator of nuclear factor-κB ligand (RANKL) antibody; Amgen Inc.] to preserve bone mass at the hip and knee and trabecular connectivity at the knee after acute SCI. Setting: patient enrollment, study drug administration and DXA scanning will be completed at the Kessler Institute for Rehabilitation (KIR) and pQCT measurements will be performed at Columbia University. A Randomized, double-blind, placebo-controlled parallel group trial.
Twenty-four subjects with acute, motor complete SCI (≤12 weeks) who have been admitted to the Kessler Institute for Rehabilitation (KIR) will be recruited for participation. The age of study participation will be males between the ages of 18 and 65 years old and females between the ages of 18 and 50 years old. Primary outcome measure will be BMD as measured by DXA and microarchitecture as measured by pQCT at the hip and knee.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||The Efficacy of Denosumab to Reduce Osteoporosis After Spinal Cord Injury|
|Study Start Date :||January 2015|
|Estimated Primary Completion Date :||May 2020|
|Estimated Study Completion Date :||May 2020|
Placebo Comparator: Placebo
A group of participants will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
Drug: Placebo (identical Denosumab volume of normal saline)
The placebo group will receive the identical volume of normal saline at parallel time points.
Other Name: Unknown at this time
A group of participants will be randomized to the experimental group and will have Denosumab (Prolia, 60 mg SC) administered at baseline, 6 and 12 months.
In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates.39,40 The rate of bone loss in the lower extremity at sites of interest in patients with acute SCI has been reported to be several-fold greater than the rate of bone loss in postmenopausal women not prescribed antiresorptive medications, which is about 3-5% per year.11,50,51 The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
Other Name: Prolia
- Bone mineral density (BMD) of the distal femur [ Time Frame: Baseline, 1, 3, 6, 12, and 18 months after Denosumab administration ]Change in BMD at the distal femur will be obtained by dual energy X-ray absorptiometry (DXA) at baseline, 1, 3, 6, 12, and 18 months after Denosumab administration.
- Bone microarchitecture of the distal femur and proximal tibia. [ Time Frame: Baseline, 12, and 18 months after Denosumab administration ]Change in microarchitecture at the distal femur and proximal tibia will be obtained by peripheral quantitative computerized tomography (pQCT) at baseline, 12, and 18 months after Denosumab administration.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01983475
|Contact: Christopher M Cirnigliaro, M.S.||973-731-3900 ext email@example.com|
|Contact: William A Bauman, M.D.||718-584-9000 ext firstname.lastname@example.org|
|United States, New Jersey|
|Kessler Institute for Rehabilitation||Recruiting|
|West Orange, New Jersey, United States, 07052|
|Contact: Christopher M Cirnigliaro, M.S. 973-731-3900 ext 2755 email@example.com|
|Contact: Steven C Kirshblum, M.D. 973-731-3900 ext 2258 firstname.lastname@example.org|
|Sub-Investigator: Christopher M Cirnigliaro, M.S.|
|Principal Investigator: Steven C Kirshblum, M.D.|
|United States, New York|
|James J. Peters VA Medical Center||Recruiting|
|Bronx, New York, United States, 10468|
|Contact: Joshua C Hobson, MS 718-584-9000 ext 3129 email@example.com|
|Contact: Pierre Asselin, MS 718-584-9000 ext 3124 firstname.lastname@example.org|
|Principal Investigator:||William A Bauman, M.D.||James J. Peters VA Medical Center|
|Principal Investigator:||Steven C Kirshblum, M.D.||Kessler Institute for Rehabilitation|